Home » Stocks » NRIX

Nurix Therapeutics, Inc. (NRIX)

Stock Price: $42.31 USD 3.07 (7.82%)
Updated November 30, 2:28 PM EST - Market open

Stock Price Chart

Key Info

Market Cap 1.64B
Revenue (ttm) 12.99M
Net Income (ttm) -36.85M
Shares Out 38.86M
EPS (ttm) -0.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 30
Last Price $42.31
Previous Close $39.24
Change ($) 3.07
Change (%) 7.82%
Day's Open 39.56
Day's Range 37.95 - 42.81
Day's Volume 59,714
52-Week Range 16.05 - 42.81

More Stats

Market Cap 1.64B
Enterprise Value 1.29B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 38.86M
Float n/a
EPS (basic) n/a
EPS (diluted) -0.95
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 844,308
Short Ratio 6.79
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 126.53
PB Ratio 4.77
Revenue 12.99M
Operating Income n/a
Net Income -36.85M
Free Cash Flow n/a
Net Cash 354.41M
Net Cash / Share 9.12
Gross Margin -107.06%
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (5)

Buy 4
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(-13.50% downside)
Current: $42.31
Target: 36.60
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-53.35-47.19
Net Income-21.70-9.43
Shares Outstanding3.292.82
Earnings Per Share-6.59-3.35
Cash & Equivalents37.8939.21
Net Cash / Debt37.8939.21
Book Value-57.71-36.85
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Nurix Therapeutics, Inc.
Country United States
Employees 122
CEO Arthur T. Sands

Stock Information

Ticker Symbol NRIX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: NRIX
IPO Date July 24, 2020


Nurix Therapeutics, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's lead product candidates in preclinical stage include NX-2127, an orally available Bruton's tyrosine kinase degrader for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B inhibitor for immuno-oncology indications. It also provides DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a class of enzymes that could modulate proteins within the cell. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc.; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was founded in 2009 and is headquartered in San Francisco, California.